Product Description: Sibofimloc (Antibiotic-202) is a first-in-class, gut-restricted, orally active FimH adhesion inhibitor extracted from patent WO2014100158A1, Compound Example 202. Sibofimloc has anti-bacterial infective activity. Sibofimloc is developed for inflammatory bowel disease (IBD)[1][2].
Applications: COVID-19-immunoregulation
Formula: C35H39NO11
References: [1]W Reinisch, et al. P568 An open-label, multicenter, phase ib, pharmacokinetic (pk) and safety study of a fimh blocker, Sibofimloc (TAK-018/EB8018), in patients with Crohn’s disease (CD), Journal of Crohn's and Colitis, Volume 14, Issue Supplement_1, January 2020: S479–S480./[2]Ramtohul, Yeeman K, et al. Preparation of mannose derivatives via coupling and click cycloaddition reactions for treating bacterial infections. From PCT Int. Appl. (2014), WO 2014100158 A1 20140626.
CAS Number: 1616113-45-1
Molecular Weight: 649.68
Compound Purity: 99.70
Research Area: Infection
Solubility: DMSO : 125 mg/mL (ultrasonic)
Target: Antibiotic;Bacterial
English
Deutsch
